Search Results

You are looking at 71 - 80 of 770 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Elizabeth G. Grubbs and Douglas B. Evans

cervical lymph node metastases from papillary carcinoma of the thyroid . Br J Surg 2001 ; 88 : 1241 – 1244 . 21. Machens A Hinze R Thomusch O Dralle H . Pattern of nodal metastasis for primary and reoperative thyroid cancer . World J Surg

Full access

Karen L. Reckamp

in patients with and without brain metastases, and has less toxicity than either the first- or second-generation EGFR TKIs. Virtually all patients who experience response to frontline EGFR TKI therapy develop resistance. The most common mechanism of

Full access

Joe Y. Chang and Vivek Verma

not. 3 , 5 In addition, brain metastases have historically been associated with a poorer prognosis and have been highly underrepresented in existing randomized trials ( Table 1 ); whether these patients receive the same benefit from local therapy as

Full access

Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg, and Cesar E. Ercole

adopting a multimodal approach consisting of neoadjuvant systemic chemotherapy followed by consolidative surgical resection in patients presenting with bulky/locally advanced nodal metastases from penile cancer. In 2013, an estimated 1570 new cases of

Full access

Himani Aggarwal, Li Li, Gebra Cuyun Carter, Kathy Fraeman, and Ariel Berger

.5%; P =.01), or distant metastases (1.8% vs 9.5%; P =.029) vs HPV-negative patients. Among HPV-positive patients, 75.5%, 12.7%, and 10.9% had squamous cell carcinoma NOS, basaloid squamous cell carcinoma, and squamous cell carcinoma large cell non

Full access

Hiram S. Cody III and Kimberly J. Van Zee

; 233 : 537 – 541 . 39 Fourquet A de la Rochfordiere A Campana F . Occult primary breast cancer with axillary metastases . In Harris JR , Lippman ME , Morrow M , Hellman S (eds). Diseases of the Breast. Philadelphia : Lippincott

Full access

Melanoma, Version 2.2013

Featured Updates to the NCCN Guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho

metastases who would be at higher risk of recurrence and who might be candidates for complete lymph node dissection or adjuvant systemic therapy. A large meta-analysis, including 71 studies and 25,240 participants, estimated the risk of nodal recurrence after

Full access

Shankar Sellappan, Adele Blackler, Wei-Li Liao, Emily O'Day, Peng Xu, Sheeno Thyparambil, Fabiola Cecchi, Todd Hembrough, and Daniel V.T. Catenacci

improve clinical outcomes. Case Presentation A 39-year-old man was diagnosed with stage IV HER2 -amplified esophagogastric cancer in January 2012 after presenting with dysphagia and back pain demonstrating vertebral metastases. The patient had

Full access

Stephanie L. Lee

of 1) increasing the sensitivity of long-term monitoring of thyroglobulin levels, 2) staging with posttherapy whole-body scan to detect local and distant metastases, and 3) facilitating the effectiveness of subsequent 131 I treatments if a large

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors at a dose of 120 mg monthly 115 , 116 ( Table 2 ). Estrogen/Hormonal Therapy: Estrogen is an antiresorptive with proven antifracture efficacy, as demonstrated